Although several studies reported that DNMT3A mutations were independently associated with poor outcomes in AML, especially in CN-AML [18,21,23,24], the impact of DNMT3A mutations in clinical decision-making remains debatable [19,20,25]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.